A Research Study About Weight Loss and Treatment Patterns With the Use of Saxenda® in Adults in Real-life Settings in Switzerland

CompletedOBSERVATIONAL
Enrollment

269

Participants

Timeline

Start Date

December 3, 2021

Primary Completion Date

April 15, 2022

Study Completion Date

April 15, 2022

Conditions
Obesity or Overweight
Interventions
DRUG

Saxenda®

"Patients will be treated with commercially available Saxenda® according to local label and to routine clinical practice at the discretion of the treating physician.~The indication is for adults who need help managing their weight based on two different body mass index (BMI) groups."

Trial Locations (1)

2860

Novo Nordisk Investigational Site, Soeborg

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT05153590 - A Research Study About Weight Loss and Treatment Patterns With the Use of Saxenda® in Adults in Real-life Settings in Switzerland | Biotech Hunter | Biotech Hunter